Aptinyx to Participate in Upcoming Investor Conferences

Aptinyx Inc. APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences:

• Cowen 41^st Annual Health Care Conference – Norbert Riedel, Ph.D., chief executive officer, will participate in the Neuropsychiatry Panel discussion at 1:20 p.m. EST on Monday, March 1, 2021; and

• H.C. Wainwright Global Life Sciences Conference – Senior management will participate in one-on-one meetings with investors throughout the conference on March 9 – 10, 2021.

The neuropsychology panel discussion will be available to view on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com and will be archived on Aptinyx's website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005152/en/